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Incidence and epidemiology 
Primary bone tumours are rare, accounting for <0.2% of malignant neoplasms 
registered in the EUROCARE database [1]. Different bone tumour subtypes have 
distinct patterns of incidence, and are each no more than 0.3 cases per 100,000 per 
year. Osteosarcoma (OS) and Ewing sarcoma (ES) have a relatively high incidence in 
the second decade of life, whereas chondrosarcoma is commoner in older age. 
 
OS is the first primary cancer of bone (incidence: 0.2–0.3 per 100,000 per year[Hans1]). 
The incidence is higher in adolescents (0.8–1.1 per 100,000 per year at age 15–19), 
where it accounts for >10% of all solid cancers. The male:femalemale: female ratio is 
1.4:1. Most osteosarcomas of younger patients arise in an extremity, while the 
proportion of axial tumour sites increases with age. Risk factors for the occurrence of 
OS include previous radiation therapy, Paget disease of bone [2], and germ-line 
genetic abnormalities associated with Li–Fraumeni syndrome, Werner syndrome, 
Rothmund–Thomson syndrome, Bloom syndrome, and hereditary retinoblastoma [3]. 
 
Chondrosarcoma (CS) is the most frequent bone sarcoma of adulthood. The incidence 
is about 0.2 per 100,000 per year[Hans2], with[p3] a median age at diagnosis between 30 
and 60 years., No gender predominance has been reported. 
 
ES is the third commonest primary malignant bone tumour. It occurs most frequently 
in children and adolescents, but is also seen in adults. Median age at diagnosis is 15 
years and there is a male predilection (1.5:1). In white Caucasians under the age of 
25 years, ES has an incidence of 0.3 per 100,000 per year [4], and it is even rarer in 
the African and Asian population. The genetic basis for the difference between ethnical 
groups has been recently linked to a common genomic germline variant, which 
extends a microsatellite, thereby facilitating the binding of the EWSR1-FLI1 chimeric 
protein to the EGR2 gene locus, leading to higher expression of the transcription factor 
early growth response 2 (EGR2) and increased susceptibility to ES {Grünewald, 
T.G.P. et al. Nat. Genet. 47, 1073–1078; 2015}. The genetic basis for this difference 
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has been recently linked to modifier genetic loci based on GGAA repeats associated 
with EGR2 gene and to loci located nearby the TARDBP gene[p4]. The most common ES 
primary sites are the extremity bones (50% of all cases) followed by pelvis, ribs and 
vertebra. However, any bone can potentially be affected and a soft-tissue origin is also 
possible, especially in adults[p5].  
 
 
Chordomas are even rarer compared to other subtypes, with an incidence of ∼0.5 per 
million per year [5]. 
 
High-grade spindle/pleomorphic sarcomas of bone: Spindle cell sarcomas of bone 
are a heterogeneous group of primary malignant bone tumours that do not fulfil the 
histological criteria for a diagnosis of osteosarcoma, chondrosarcoma or Ewing’s 




Giant cell tumor of bone is a benign intramedullary bone tumor composed of 
mononuclear cells and osteoclast-like multinucleated giant cells, with a variable and 
unpredictable potential for aggressive growth. It represents approximately 5% of 
primary bone tumors and about 15-20% of benign bone tumors. (ref: Picci et al.,  Atlas 
of musculoskeletal tumors and tumorlike lesions; Klenke FM et al, Giant cell tumor of 
bone: risk factors for recurrence. Clin Orthop Relat Res. 2011;469(2):591–9.) 
Giant cell tumor of bone[p7]? 
 
Diagnosis and pathology / molecular biology 
 
The medical history should focus on characteristic symptoms characteristics such as 
duration, intensity and timing of pain. The presence of persistent non-mechanical bone 
pain, predominantly at night, should cause concern and prompt a radiological 
assessment. Swelling and functional impairment can be present if the tumour has 
progressed through the cortex and distended the periosteum, but they are often later 
signs. The differential diagnosies of a bone sarcomalesion includes osteomyelitis, 
benign tumours and bone metastases, all of which outnumber primary bone sarcomas 
[6-8]. The diagnosis can be strongly oriented by the age of the patient. Under 5 years, 
a destructive bone lesion could be interpreted predominantly as either metastatic 
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neuroblastoma or Langerhans cell histiocytosis (LCH)eosinophilic granuloma. Above 
5 years, the likelihood of a primary bone sarcoma is higher. In adult patients, after 40 
years of age, bone metastases and myeloma will be the most common diagnoses [9].  
 
Conventional radiograph in two planes is the first radiological investigation. When the 
diagnosis of malignancy cannot be excluded with certainty on radiographs, the next 
step should be magnetic resonance imaging (MRI) of the whole compartment with 
adjacent joints, which is regarded today as the best modality for local staging of 
extremity and pelvic tumours [10]. Computed tomography (CT) can may provide 
additional information, by allowing a better visualization of calcifications, periosteal 
bone formation, medullary extension[p8] and cortical destruction, but is not routinely 
required.  
 
All patients with a bone lesion which is likely to be a primary malignant bone tumour 
on a radiological basis should be referred to a bone sarcoma centre or to an institution 
belonging to a specialised sarcoma network [11-14]. Children and adolescents should 
be referred to centres which in addition provide age-specific expertise. The biopsy and 
the pathological diagnosis require expertise in the field and should be discussed in a 
multidisciplinary setting. 
 
The biopsy of a suspected primary malignant bone tumour should be carried out at the 
reference centre by either the surgical team who will perform the definitive tumour 
resection or by a dedicated interventional radiologist [11-14]. In most patients, a core-
needle biopsy, taken under imaging control, can be an appropriate alternative to open 
biopsy. The contamination of surrounding tissue should be minimized and adequate 
multiple sampling of representative areas must always be provided. To ensure that the 
tissue is representative of the tumour, X-rays of the biopsy location are recommended 
and in some circumstances tumor imprints (touch preps) or a frozen section may be 
required[p9]. SinceWhen osteomyelitis is in the radiological differential diagnosis, a 
potential differential diagnosis, samples should may be sent for microbiological culture[p10] 
if sufficient material is available in all cases[JB11]. If an open biopsy is neededperformed[p12], it 
should be carried out using a longitudinal incision. In aggressive and malignant 
tumours of bone, the biopsy tract and the channels through which drains have been 
placed must be considered to be potentially contaminated and must later be removed 
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together with the resection specimen, in an effort to minimize the risk of a local 
recurrence. Therefore, biopsy tracts should be clearly marked by means of a small 
incision or an ink tattoo to ensure that the location is recognised at the time of the 
definitive procedure. In cases of spinal column involvement, laminectomy or 
decompression should be avoided unless necessary to relieve spinal cord 
compression,compression and tissue sampling must be performed whenever a bone 
sarcoma is suspected.  
 
Samples must be interpreted by an experienced bone sarcoma pathologist, in 
collaboration with the radiologist, and discussed in a multidisciplinary team. The 
request form should be filled with all the details that might be relevant for diagnosis, 
including patient’s age, the site of the tumour, radiological findings, if there are multiple 
lesions, family history, and, for surgical specimens, eventual preoperative treatments. 
 
With the increasing capability for accurate molecular diagnosis and next generation 
DNA deep sequencing technologies of DNA or RNA, samples should be quickly 
submitted for pathological assessment. The collection of fresh frozen tissue is strongly 
encouraged, to enable molecular diagnostics. As an alternative, decalcification in 
EDTA instead of formic acid can be considered. Upon arrival[JB13], and before formalin 
fixation, Ttumour imprints (touch preps) can be considered taken[p14] [JB15](might be useful for 
tumour-specific translocation by fluorescence in situ hybridisation, FISH in some 
institutions), and tissue/cell suspensions should be kept frozen in cryomolds for later 
DNA and RNA extraction. A further option is to establish primary cell cultures for 
cytogenetics and other studies, such as patient-derived xenografts within research 
protocols[p16] with informed consent. The collection of fresh frozen tissue and tumour 
imprints (touch preps) is encouraged, because future current molecular pathology 
assessments might be iperformed n the patient’s interest. Informed consent for tumour 
banking should be routinely sought, enabling later analyses for research, depending 
on local regulations.  
 
The nature of the bone specimen received for pathology reporting should be recorded, 
i.e. needle biopsy, curettage or excision (e.g. segmental resection, limb salvage 
amputation, or other complex resection, such as a hemi-pelvectomy). It is usually 
necessary to decalcify the bone tumour biopsy using specific standard operating 
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procedures. The histological features of the tumour should be described and the 
tumour type (and subtype) specified according to the 2013 most recent version of the 
World[p17] Health Organization (WHO) Classification [15]. The results of relevant ancillary 
investigations (e.g. immunohistochemistry or molecular assessments) should be 
accurately recorded [16]. Molecular diagnostics techniques currently used include 
FISH, RT-PCR, and next generation sequencing technologies. Examples include 
translocation detection in ES and mesenchymal CS, The latter have revealed 
diagnostic information for OS, ES translocation types, histone subtype mutations in 
giant cell tumour of bone isocitrate dehydrogenase (IDH1 and IDH2) mutations in  and 
driver mutation frequency in conventional chondrosarcoma, and MDM2 amplification 
in parosteal and intramedullary low grade osteosarcoma and are strongly 
recommended in the diagnostic work-up of any small round cell bone sarcoma. [JB18] 
 
For surgical specimens, the size (measured in three dimensions in mm) of the tumour 
in the resected bone should be recorded.  The pathology report should also describe 
the extent of local tumour spread, including involvement of specific anatomical soft 
tissue and bone compartments. It should be recorded whether the resection margins 
are either clear or infiltrated and the distance (in mm) of tumour from the nearest 
resection margin measured. Photographs should be taken of the intact specimen and 
of the tumour slabs after sawing. A complete, representative slab of the tumour, 
usually in the longitudinal axis as guided by the radiological images, should be 
embedded for microscopy in a grid-manner. This is especially relevant after 
neoadjuvant chemotherapy to assess response. The tumour should be coded using 
Systematic Nomenclature of Medicine (SNOMED) or International Classification of 
Diseases for Oncology (ICD-O) codes[p19]. 
 
Staging and risk assessment 
 
All cases of suspected bone tumours should be formally discussed oin a 
multidisciplinary teambasis with the radiologist who has interpreted the imaging, the 
pathologist who has reviewed the biopsy material, the surgeon, the radiation and the 
medical and/or pediatric oncologist.  The output of the multidisciplinary discussion 
must be recorded, in order to minimise the risk of errors in diagnosis, staging, risk 
assessment and treatment. 
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Several staging systems for bone tumours are in use [17, 18][p20]. However, none of 
them is perfect or generally accepted. Generally, tumour burden (volume) and the 
presence of detectable metastases are the two main factors that are taken into 
consideration in the clinical staging of these diseases. General staging should be 
carried out to assess the extent of distant disease, including bone scintigraphy, chest 
radiographs and CT [19]. Whole-body MRI and positron emission tomography 
(PET)/CT or PET/MRI are increasingly utilised for staging (including skip bone 
lesions) [20][p21]. Additional appropriate imaging studies and biopsies can be taken from 
suspicious sites, as the exact staging of the disease has an impact on treatment and 
outcome. No specific laboratory tests for the diagnosis of bone sarcoma are routinely 
available. Baseline serum analysis in ES and OS should include alkaline 
phosphatase (AP) and lactate dehydrogenase (LDH) given their proven prognostic 
value [21, 22]. 
Next[p22] generation sequencing technologies performed on tumor tissue have revealed 
diagnostic information for OS,[JB23] ES and other round cell sarcomas (translocations), 
mesenchymal chondrosarcoma (Hes related family BHLH transcription factor with 
YRPW motif 1 - nuclear receptor coactivator 2 HEY1-NCOA2),  types, histone subtype 
mutations in giant cell tumour of bone and conventional driver mutation frequency in 
chondrosarcoma (IDH) and giant cell tumor of bone (H3 histone family member 3A 
(H3F3A)).  
 
A pathological fracture may lead to the dissemination of tumour cells into surrounding 
tissues and increase the risk of local recurrence. In cases of fracture, internal fixation 
is contraindicated as it disseminates the tumour further into both bone and soft tissues 
and increases the risk of local recurrence. External splintage is recommended[p24].  
 
Chemotherapy can result in renal, cardiac and auditory dysfunction. Before starting 
the treatment, baseline renal function testing, assessment of cardiac function and 
audiogram (in the case of platinum derivatives) should be performed. Sperm storage 
is recommended for male patients of reproductive age. For female patients, a fertility 




Treatment (locoregional and advanced disease) 
 
Given the rarity of the disease and the complexity of management, the accepted 
standard for bone sarcomas is treatment at reference centres and/or within reference 
networks able to provide access to the full spectrum of care and age-specific expertise. 
In these centres/networks, therapy is usually given within either the framework of 
prospective, often collaborative, clinical studies or established treatment protocols. In 
the case of high-grade osteosarcoma, ES or pleomorphic sarcoma, following biopsy 
proven-diagnosis, primary dose intense [JW26]chemotherapy[p27] is indicated. 
 
osteosarcoma 
Osteosarcoma usually arises in the metaphysis of a long bone, most commonly 
around the knee in children and adolescents. Involvement of the axial skeleton and 
craniofacial bones is primarily observed in older patients. High-grade osteosarcoma 
frequently metastasizes, the lung being the most frequent metastatic site by far, 
followed by distant bones. 
 
Conventional osteosarcoma is always a high-grade malignancy, and accounts for 75% 
of all high-grade osteosarcomas. Low-grade central and parosteal osteosarcoma are 
low[p28]-grade malignancies though may grow large and invade the medulla of bone, and 
transform to high grade sarcoma, whereas periosteal osteosarcoma is an 
intermediate-grade chondroblastic osteosarcoma, sometimes difficult to distinguish 
from high grade surface osteosarcoma. Adverse prognostic or predictive factors for 
conventional osteosarcoma include detectable primary metastases, axial or proximal 
extremity tumour site, large tumour size, elevated serum AP or LDH and older age 
[21] [II[AF29]I, B]. As mentioned above, sStaging should include local imaging studies, 
specifically plain radiographs and MRI of the whole affected bone[p30]extremity[p31].  
 
Curative treatment of high-grade osteosarcoma consists of chemotherapy and 
surgery. Compared with surgery alone, multimodal chemotherapy treatment of high-
grade localised osteosarcoma increases disease-free survival probability from 10%–
20% to >60%. In general, chemotherapy is administered before and after surgery, 
although a formal proof that giving chemotherapy preoperatively improves survival is 
lacking. The extent of histological response to preoperative chemotherapy predicts 
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survival [21, 23, 24]. Altering postoperative chemotherapy in poor responders to 
preoperative systemic therapy proved ineffective, yet was associated with increased 
acute and late toxicity in a large prospective randomized trial.  [JW32] 
 
Low-grade central and parosteal osteosarcoma are malignancies with a lower 
metastatic potential, which are treated by surgery alone [LOE IIIIV, GOR B]. Although 
chemotherapy has been used for periosteal osteosarcomas, no benefit for 
chemotherapy was shown in two retrospective analyses [25, 26], and its use should 
be discouraged in this setting (LOE IV, GOR D).  
 
Surgery should be carried out by a surgical team familiar with the wide range of 
surgical reconstructive options.. Pediatric and adolescent patients need to be treated 
by surgeons with great experience in the field of pediatric bone tumors, including age-
specific reconstruction challenges, such as the reconstruction of growing bones. The 
goal of surgery is to safely remove the tumour and yet preserve as much function as 
possible, striving to obtain microscopically clear surgical margins [24]. Most patients 
should be considered candidates for limb salvage. Either intra-lesional or marginal 
margins increase the local relapse rate, which is associated with reduced overall 
survival (OS). Thus, clear margins are the first goal of surgery [III[AF33], B]. Areas where 
there is suspicion of close margins should be marked on the surgical specimen sent 
to pathology. 
 
Pathological fracture does not necessarily necessitate an amputation. In chemo-
sensitive tumours, primary neoadjuvant chemotherapy can be used with the 
expectation that a good responseit[p34] will allow the fracture haematoma to contract and 
allow subsequent resection of the tumour and the involved soft tissues [27]. 
 
Doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide, the latter usually 
combined with etoposide[JW35][p36], have anti-tumour activity in osteosarcoma [28-31] [I, A]. 
[AF37]Doxorubicin, cisplatin and high-dose methotrexate (MAP) are most frequently used as 
the basis of treatment [31] [II, A]. These drugs should be administered with adequate 
supportive care by experienced paediatric oncologists or medical oncologists at 
reference institutions with appropriate infrastructure and a multidisciplinary treatment 
approach [29]. Most current protocols include a period of pre-operative chemotherapy, 
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to facilitate local surgical treatment and to allow the assessment of tumour response 
[32, 33] although this has not been proven to entail a survival benefit per se over 
postoperative chemotherapy alone [JW38]. Treatment is commonly given over periods of 6–
10 months [31]. The EURAMOS 1 prospective trial aimed to establish whether 
pegylated interferon 2b, in addition to standard MAP chemotherapy given post-
operatively, could improve outcome in patients with good histological response to 
preoperative MAP.   The results showed that many patients failed to start and complete 
interferon treatment, and there was overall no significant survival advantage [LOE I, 
GOR 1CC][34].  Also, the study evaluated if altering postoperative chemotherapy in 
poor responders to preoperative systemic therapy might have any impact on outcome, 
and again no survival benefit was proven. In case of poor pathological response to 
preoperative MAP regimen, the postoperative addition of ifosfamide and etoposide to 
MAP failed to improve the survival and increased the risk of secondary malignancy 
compared to those patients treated with MAP regimen only (LOE I, GOR D)[34]. 
Whenever possible, patients with osteosarcoma should receive chemotherapy in the 
context of prospective studies. 
 
Innate immune-modulation has been attempted in OS with some agents, e.g. 
interferon [35] and muramyl tripeptide. The use of interferon failed to show a survival 
advantage in patients good responderswith a good histological response to a MAP 
preoperative regimen[p39]. Muramyl tripeptide added to postoperative chemotherapy was 
associated with a significantsubstantial advantage in overall survivalOS and a non-
significant trend in event-free survival in one large randomised trial [36, 37] [LOE II, 
GOR C] [36, 37]. Muramyl tripeptide has been approved in Europe for patients <30 
years of age with completely resected localised osteosarcoma, but it is not reimbursed 
in all European countries. There is no consensus in the sarcoma community on the 
use of this drug, because of weaknesses of the only trial available [36]. Further studies 
are definitely needed to identify any subgroup of patients who could benefit from 
immune modifying agents. 
 
Dynamic MRI is reliable to evaluate changes in tumour vascularity and to give 
additional information on tumor response to primary chemotherapy [38, 39] [III, [AF40]B]. 
Similarly, the value of diffusion MRI is currently under evaluation [38].  
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Radiation[p41] therapy should not be considered in cases where surgery with clear margins 
can be performed. When surgery cannot achieve wide margins, radiation therapy is 
recommended to try to extend the progression-free interval This should preferably be 
discussed in a multidisciplinary team beforehand and with the patient, it should be 
clear at the time of surgery that the goal is not an R0 resection.. New radiation therapy 
techniques (e.g. proton beam and carbon ion therapy) should be considered 
particularly for unresectable primary tumours.  
 
The multimodal treatment principles detailed above were generated in children, 
adolescents and young adults with high-grade central osteosarcoma, but also relate 
to adults at least up to the age of 60[p42] [40] [LOE III, GOR B]. Adult Older patients (>40 
years) may require tailored regimens, especially as far as high-dose methotrexate is 
concerned, in particular for those aged >40. Some studies have put a threshold of 25 
to remove HDMTX from the inducation regimen (40b[p43]) Doxorubicin plus cisplatin and/or 
ifosfamide are commonly used with age-adapted doses. Recently the addition of 
zoledronic acid was tested in a randomized setting and  failed to demonstrate an 
improvement for  relapse-fre or overall suvivalRFS, OS[p44] or histological response. Its 
use is therefore not recommended outside of a clinical trial (LOE I, GOR D).  
 
High-grade craniofacial osteosarcoma should be treated the same way as high-grade 
osteosarcoma of other locations, although evidence is lacking due to the absence of 
selective clinical studies in this patient population [IV, C]. Radiation therapy, if available 
proton beam/carbon ion radiation therapy, should be considered, preferably within 
clinical studies, when complete surgery is unfeasible. Primary metastatic 
osteosarcoma patients are treated with a curative intent following the same principles 
of non-metastatic osteosarcomas [41]. In fact, there are subsets of patients who can 
have a very similar prognosis to that of localised disease, provided surgical removal 
of all known metastatic deposits is achievable [42] [III, B]. Approximately 25% of all 
patients with primary metastatic osteosarcoma and >40% of those who achieve a 
complete surgical remission may become long-term survivors. 
 
High-grade craniofacial osteosarcoma should be treated the same way as high-grade 
osteosarcoma of other locations, although prospective evidence is lacking due to the 
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absence of selective clinical studies in this patient population [LOE IV, GOR C]. The 
delivery of all chemotherapy before surgery, using PET monitoring to ensure sustained 
response[p45], has possible advantage in this population and others in who the recovery 
from very complex or morbid surgery may not allow timely reintroduction of post-
operative chemotherapy[43]. Radiation therapy,  if available proton beam/carbon ion 
radiation therapy, [JW46]should be considered, preferably within clinical studies, when 
complete surgery is not  unfeasible. The value of proton beam/carbon ion radiation 
therapy in this setting is currently under study.  
 
The management of recurrent osteosarcoma needs to take into account the timing of 
recurrences/metastases, the number of metastases and the metastatic sites. CT scan 
can over- and under-estimate the number of pulmonary metastases, but the recent 
results have improved with spiral CT. The treatment of recurrent osteosarcoma is 
primarily surgical in the case of isolated lung metastases. Complete removal of all 
metastases must be attempted [LOE III, GOR B], as the disease is otherwise almost 
universally fatal, while more than a third of patients with a complete second surgical 
remission survive for >5 years [44]. Even patients with subsequent recurrences may 
be cured as long as recurrences are resectable, and repeated thoracotomies are often 
warranted [44]. For lung metastases, sStereotactic radiotherapy, radiofrequency 
ablation or cryotherapy for lung metastases might be used as an alternative options in 
patients unfit for surgery. Some groups also consider radiofrequency ablation 
(Debaere 2015, Saumet 2015) and stereotactic radiotherapy ( Yu 2017) potential 
alternative local treatment options for small size lung or bone metastases. 
 
The role of second-line chemotherapy for recurrent osteosarcoma is much less well 
defined. Treatment choice may take into account the prior disease-free interval, and 
often includes ifosfamide or cyclophosphamide, possibly in association with etoposide 
and/or carboplatin (LOE III, GOR B), and other active drugs including gemcitabine and 
docetaxel (LOE IV, GOR C) and sorafenib if available (LOE III, GOR B[p47]). In the two 
largest reported series, the use of second-line chemotherapy correlated with limited 
prolongation of survival in patients with inoperable metastatic recurrences, while a 
positive correlation in operable disease was observed in only one of the two [42, 44]. 
However radiologic responses and clinical benefit are commonly witnessed so that its 
use should always be considered[p48]. Treatment choice may take into account the prior 
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disease-free interval, and often includes ifosfamide ± etoposide ± carboplatin, and 
other active drugs (e.g. gemcitabine and docetaxel; sorafenib).  
 
Radiation therapy, including internal radiotherapy targeting areas of increased bone 
turnover,  may have a role in palliation [45]. In general, despite second-line treatment, 
the prognosis of recurrent unresectable[p49] disease has remained poor, with a long-term 
post-relapse survival of <20%. 
 
Ewing sarcoma 
ES is a small, blue, round-cell tumour, periodic acid-Schiff positive and CD99 (MIC2)-
positive. All ES are high-grade tumours. They can arise both from bone and soft 
tissues, displaying the same behaviour in principle. 
 
The definitive diagnosis is made by biopsy, providing a sufficient material for 
conventional histology, immunohistochemistry, molecular pathology and biobanking. 
Molecular biology studies have shown that almost all of these tumours share a 
common TET-ETS gene rearrangement involving the EWSR1 gene on chromosome 
22 [46, 47]. In most cases, this involves a reciprocal translocation t(11;22)(q24;q12) 
[48], but t(21;22)(q22;q12) [49, 50] and others may also occur [t(7;22), t(17;22), and 
t(2;22)]. In the last years, new small round cell sarcoma entities have been recognized 
to have a Ewing- like[JB50] histopathology pattern, with and novel translocations, among 
which  such as BCOR-rearranged sarcoma preferentially affects the bone CCNB3 (in 
the bone), and CIC-FOXO4 or CIC-DUX4 (mainly in the soft tissues EWS RNA binding 
protein 1 - nuclear factor of activated T-cells 2 (EWSR1-NFATc2), FUS RNA binding 
protein - nuclear factor of activated T-cells 2 (FUS-NFATc2), capicua transcriptional 
repressor – forkhead box O4 (CIC-FOXO4) or capicua transcriptional repressor – 
double homeobox 4 (CIC-DUX4) ). EWSR1-NFATc2, FUS-NFATc2, CIC-FOXO4 or 
CIC-DUX4 tranlocations are other examples of recurrent molecular alterations found 
in these malignancies. Current investigations have shown that tumour biology and 
prognosis actually differs from that of classical ES, making the diagnosis and 
identification of these cases mandatory.In a minority of tumours with Ewing- like 
histopathology pattern, novel translocations have been identified such as BCOR-
CCNB3, EWSR1-NFATc2, FUS-NFATc2, CIC-FOXO4 or CIC-DUX4. Further 
investigations implicate that tumour biology may differ from classical ES. However, 
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given the low incidence of these rare tumors, no final conclusion is possible as to how 
their approach should be superimposablecurrently there is little evidence to support 
different approaches to their management. Inclusion in prospective registries is 
worthwhile (EURACAN G1[p51][p52]?)..  
 
  
Although most ES can be recognised with classical haematoxylin and eosin (H&E) 
stain and immunohistochemistry , CD99 expression,molecular confirmation is 
mandatory.  When EWSR1 and FUS are not rearranged, further workup for other, rare 
round cell sarcomas including BCL6 corepressor (BCOR) rearranged round cell 
sarcoma is required[p53]. CIC, and BCOR gene rearrangement detection is mandatory[JB54] in 
all patients with small round cell sarcomas including[p55] CD99, EWS translocation 
detection is recommended in all patients and mandatory when the clinical–pathological 
presentation is unusual, or the histological diagnosis is doubtful [II, B]. A reference 
laboratory for ES diagnosis should have access to different techniques including both 
FISH,  and reverse transcription polymerase chain reaction (RT–PCR) or as well as 
next generation sequencing[JB56] [50]. The laboratory should be enrolled in an external 
quality assurance programme. RT–PCR is the investigation of choice [JB57]Wwhen frozen 
tissue is available, techniques that identify both fusion partners, i.e. RT-PCR or 
anchored multiplex PCR based targeted NGS are the techniques of choice. although 
RNASeq The latter can also be applied to non-decalcified or EDTA decalcified FFPE. 
is increasingly being utilised, and FISH is a good choice only when only formalin-fixed 
paraffin-embedded tissue (or touch preps (imprints)) are available. There are several 
commercial sources for EWSR1 EWS break-apart probes. Assays using EWSR1 
break-apart probes do not detect EWS–FLI1 fusions, but only EWSR1 EWS 
rearrangements, which should not be a problem when interpreted in the appropriate 
clinical and pathological context.  Next generation sequencing should be considered 
when no typical translocation has been detected by conventional methods. Detection 
of rare translocations is important especially in the context of other rare round cell 
Ewing like small round blue cell sarcomas with more aggressive clinical course 
carrying CIC or BCOR rearrangementthe CIC-DUX4 fusion gene. However, 




Bone marrow biopsies and aspirates (from sites distant to the primary or known 
metastatic lesions) may be considered in the staging, in the face of a very low 
incidence of bone marrow metastases in localised disease, especially if PET scan was 
carried outis negative[p59]. The added prognostic value of molecular positivity over light 
microscopic evaluation has not yet been proven [LOE IV, GOR C]. 
 
Between 20% and 25% of patients are diagnosed with metastatic disease (10%: 
lung—10%: bones/bone marrow—5%: combinations, or others) [51, 52]. Staging must 
be oriented to detect lung, bone and bone marrow metastases[p60]. Multiple bone 
metastases confer a poorer outcome than lung/pleural metastases (<20% compared 
with 20%–40% 5-year survival). Other known prognostic factors are tumour size or 
volume, serum LDH levels, axial localisation or older age (>15 years). A poor 
histological response to preoperative chemotherapy and incomplete or no surgery for 
local therapy are further adverse prognostic factors [22, 53-57] [II[AF61], B]. Molecular 
structure of fusion transcripts has not been shown to be of prognostic value with 
current treatment protocols, with the exception of CIC-DUX4 translocation[EdA62][BB(CM63][p64][JB65].. (59new) 
Genomic analysis with the assessment of copy number variation has been shown to 
be of prognostic value [58, 59]. In addition Stag2, TP53 and CDKN2A mutations confer 
poorer outcomes. With surgery or radiotherapy alone, 5-year survival was <10%. With 
the currently recommended multimodal approaches including chemotherapy, survival 
is ∼60%–75% in localised and ∼20%–40% in metastatic disease, respectively, 
depending on metastatic sites and burden. 
 
Current trials employ 3–6 cycles of initial combination chemotherapy after biopsy, 
followed by local therapy, and another 6–10 cycles of chemotherapy usually applied 
at 2- to 3-week intervals. Treatment duration is thus 10–12 months. Agents considered 
to be most active include doxorubicin, cyclophosphamide, ifosfamide, vincristine, 
dactinomycin and etoposide [60-64]. Almost all active protocols are based on five- to 
six-drug combinations of these substances [LOE I, GOR A]. Chemotherapy intensity 
(interval compression) is was positively associated with outcome in pediatric and 
adolescent (<18 years) patients[p66] in a prospective North American study.  
 
High-dose chemotherapy with haematopoietic stem-cell transplantation...:The use of 
high dose chemotherapy with escalated alkylating agent dose and blood stem cell 
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rescue has attracted much attention in ES since the 1970s [65].  Only recently have 
the results of randomised studies with busulfan and melphalan indicated that this 
approach results in a survival advantage for tightly defined and highly selected patients 
with poor response to induction [Hans67]chemotherapy (LOE II, GOR A)[66]. No such 
advantage was evident for patients presenting with pulmonary metastases (LOE II, 
GOR D).  
IIA 
 
In contrast to OS, ES[p68] is a more radiosensitive tumour than OS.  The goal of local 
therapy for the primary tumour is to ensure that the entire volume of tissue involved at 
diagnosis is treated.  Complete surgical excision, where feasible, is regarded as the 
best modality of local control, given the higher risk of local recurrence when 
radiotherapy is used as the sole treatment of the primary tumour. Surgery must involve 
excision of all tissues originally involved with tumour, not just the tissue that is left after 
chemotherapy shrinkage or be supplemented by radiotherapy. Radiotherapy alone (in 
the range of 45–60 Gy, depending on location) should be applied if complete surgical 
excision is impossible. Postoperative radiotherapy should be given in cases of 
inadequate surgical margins and discussed when histological response in the surgical 
specimen was poor (i.e. >10% viable tumour cells) [55] [LOE IV, GOR B]. The dose of 
postoperative radiation therapy is also 45–60 Gy, depending on margins, response 
and location. Intralesional surgery must be avoided, as there is no benefit when 
compared with radiation therapy alone [55]. Change in the size of the soft tissue mass 
is easily evaluated on MRI and is a good predictor of tumour response [38, 39]. 
Dynamic MRI is not as reliable as in osteosarcoma [39], as remaining small tumour 
foci may not be detected. Sequential FDG-PET evaluation might be of additional value 
[67]. 
 
The treatment of adult patients follows the same principles as for ES in typical age 
groups. However, tolerability of therapies in older patients needs to be taken into 
account when transferring treatment protocols conceived for children and patients of 
age ≤40–50 years. Treatment of patients with extraskeletal ES follows the same 
principles as for bone ES, thus incorporating chemotherapy in all cases as well as 
postoperative radiation therapy in most cases, with the possible exception of 
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superficial lesions. For extraskeletal ES, postoperative radiation therapy is generally 
used, with the exception of good prognosis, superficial ES. 
 
Patients with metastases at diagnosis treated with the same treatment approach as 
patients with localised disease, have a worse prognosis. In patients with lung 
metastases, whole-lung irradiation may confer a survival advantage [LOE II, GOR C] 
[56]. [II, B]. The role of surgical resection of residual metastases is less well defined 
when used alone without chemotherapy.  
For patients presenting with extrapulmonary metastases, survival is even worse, less 
than 20% [68]. Chemotherapy is similar as for localised disease but responses are 
less durable. Treatment of the primary tumour is often appropriate, especially in the 
presence of responding metastatic disease. There is no formal evidence either for or 
against Observational studies indicate no advantage for high dose chemotherapy in 
this situation, so that its uptake differs between centers. Nand[p69] no randomised studies 
have been reported for this approach. 
 Several non-randomised trials have assessed the value of more intensive, time-
compressed or high-dose chemotherapy approaches, followed by autologous stem 
cell rescue. Ongoing[JW70] 
 
 
In patients with lung metastases, whole-lung irradiation may confer a survival 
advantage [II, B]. The role of surgical resection of residual metastases is less well 




Patients with multiple bone or bone marrow metastases and those with recurrent 
disease still fare poorly, with 5-year survival rates of ∼20%. Despite this, local control 
of bone metastases with either surgery or radiation therapy is recommended. 
 
Recurrent ES, whether local or with distant metastases is almost always fatal even 
though further responses to chemotherapy are frequent and valuable. The only 
prognostic factor identified in relapsed patients seems to be time to relapse: patients 
relapsing later than 2 years from initial diagnosis have a better outcome [69] [III[AF71], B]. 
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Doxorubicin therapy is usually no longer feasible due to previously achieved 
cumulative doses. Chemotherapy regimens in relapse situations are not standardised 
and includes alkylating agents (cyclophosphamide and high-dose ifosfamide)  [70] in 
combination with topoisomerase inhibitors (etoposide and topotecan), irinotecan with 
temozolomide [LOE III,GOR B] [71, 72] or gemcitabine and docetaxel, or high-dose 
ifosfamide or carboplatin with etoposide [71, 72][BJ72]. The relative advantages of these 
different regimens are currently being tested in an international randomised study[p73]. 
Observational studies of high dose chemotherapy indicate that for selected patients 
(those with a disease free interval of 18-24[p74] months, with no extra-pulmonary disease 
and a complete remission before high-dose chemotherapy), use of high- dose 
chemotherapy can be associated with prolonged survival[p75].[Hans76] 
 
high-grade spindle/pleomorphic sarcomas of bone  
Pleomorphic sarcomas of bone comprise a diagnostically heterogeneous group of 
malignant tumours including undifferentiated pleomorphic sarcoma [16, 73, 74][BJ77]. They 
arise in a similar age group to chondrosarcoma, but the skeletal distribution is more 
like osteosarcoma. They typically present with pain and have a high incidence of 
fractures at presentation. They represent between 2% and 5% of primary bone 
malignancies. Males are more frequently affected than females. An association with 
pre-existing disease (Paget’s disease or bone infarct) or history of previous irradiation 
has been reported. It is not unusual for a spindle cell sarcoma to be found to be either 
a dedifferentiated chondrosarcoma or osteosarcoma after examining further different 
sections of the resection. Therefore, the diagnosis should be established in a 
multidisciplinary setting and IDH mutation analysis should be considered when the 
radiological images suggest a chondrosarcoma. 
 
Pleomorphic sarcomas typically present in older patients with a lytic lesion in bone. In 
many, the differential diagnosis will be against metastases. Full staging and biopsy 
are required to reach a diagnosis. Pathological fractures are common and should not 
undergo internal fixation before biopsy[p78]. Treatment strategies mimic those of 
osteosarcoma, with chemotherapy and complete en bloc resection including any soft 
tissue component. Their sensitivity to chemotherapy is poorly known and studies on 
specific histologies, as currently defined (especially after reappraisal of histologies 
previously known as MFH), are highly required[p79]. Radiation therapy may be considered 
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in inoperable lesions. A global effort to collect these cases would be helpful to establish 




Most chondrosarcomas arise as primary malignant tumours. The majority are low 
grade, locally aggressive, non-metastasising tumours (atypical cartilaginous tumour / 
chondrosarcoma grade I), rather than high grade (grades II–III) [75]. Grade 1 
chondrosarcomas can be labelled atypical cartilaginous hondrogenic tumours, as it is 
currently defined by the WHO 2013, [Hans80]since they usually do not metastasise (ref to be 
added 78new). One should be aware that gradeGrade I chondrosarcomas may be 
treated with radiation therapy when located at critical sites such as the skull base. Most 
chondrosarcomas arise centrally in the metaphyseal region of long bones, but they 
can also develop in flat bones such as pelvis, rib and scapula. High-grade 
chondrosarcoma frequently arises in the axial skeleton and long bones. 
Chondrosarcoma can arise in pre-existing benign lesions such as enchondroma and 
osteochondroma. In these circumstances, they are referred to as secondary central 
chondrosarcoma and secondary peripheral chondrosarcomas, respectively. The 
majority of chondrosarcomas are of the conventional subtype, but rarer subtypes 
include mesenchymal and clear-cell chondrosarcoma [76, 77]. In rare circumstances, 
conventional chondrosarcomas can ‘dedifferentiate’ into a very high-grade tumour with 
a dismal prognosis: the so-called de-differentiated chondrosarcoma [76, 77]. Most 
chondrosarcomas are solitary, but they can occur as multiple lesions in syndromic 
patients with multiple osteochondromas and enchondromatosis. 
 
Most chondrosarcomas present with a painless mass. Pain at the site of a 
cartilaginous lesion may be an indicator of malignancy. In the case of 
chondrosarcoma, a contrast-enhanced MRI can reveal high-grade areas. This 
provides a useful guide to the site of biopsy [78]. For large axial and pelvic 
chondrosarcoma, heterogeneity is common and most lesions contain high grade 
elements.  The differentiation between benign enchondroma or osteochondroma and 
malignant [JB81]atypical cartilaginous tumor / grade I chondrosarcoma grade I can be 
difficult, but dynamic contrast-enhanced MRI can give hints[p82]. In the phalanges of the 
hands and feet, malignancy is extremely rare, but in the other long bones central 
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cartilaginous lesions should be considered atypical cartilaginous tumour low-grade 
chondrosarcoma unless proven otherwise [76]. 
 
Inoperable, locally advanced and metastatic high-grade chondrosarcomas have a 
poor prognosis [76, 77]. Prognosis depends on histological grade. However, 
histological classification is subject to variability in interpretation, with grade II and III 
chondrosarcomas often grouped together even though there is a wide spectrum of 
outcome and heterogeneity of grade elements within tumours [75]. Also, grade I 
tumours (atypical cartilaginous hondrogenic tumours) are not necessarily curable in 
all cases, mainly due to problematic local recurrence or progression to high grade. In 
particular, dedifferentiated chondrosarcomas are aggressive and frequently 
metastasise [76]. 
 
Assessing the grade of chondrosarcomas is difficult and discrepant diagnoses are 
common even among experts [75]. Atypical cartilaginous Low-grade cartilage tumours 
are unlikely to metastasise, but may recur locally. Atypical cartilaginous tumours 
Grade I central chondrosarcomas in the long bones of the limbs can be managed by 
curettage with or without local adjuvant (e.g. phenol, cement and cryotherapy), with a 
high chance of success. Low-grade peripheral chondrosarcomas (arising from 
osteochondromas) should be surgically excised, aiming to excise the tumour with a 
covering of normal tissue over it.  Higher grade chondrosarcomas (Grade II and III) 
and all chondrosarcomas of the pelvis or axial skeleton should be surgically excised 
with wide margins. 
 
Evidence suggests that mesenchymal chondrosarcoma is more sensitive to 
chemotherapy and therefore are usually considered for adjuvant or neoadjuvant 
therapy (LOE IV, GOR B) [79, 80] [V, B]. Most authors suggest a Ewing-type 
chemotherapy regimen.  
 
Dedifferentiated chondrosarcoma is often treated as a high-grade bone sarcoma, with 
therapies that need to be adapted to patient’s age [81, 82] [LOE V, GOR C]. There is 
a very high risk of local recurrence following excision of dedifferentiated 
chondrosarcoma, particularly in the presence of a pathological fracture. If wide 
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margins cannot be reliably achieved with limb salvage, then amputation should be 
considered. 
 
The role of radiotherapy in chondrosarcoma is limited, but may be appropriate in highly 
selected cases or for palliation. Excellent outcomes have been reported for skull base 
chondrosarcomas with high-dose radiation therapy, including proton beam or carbon 
ion radiotherapy, achieving 80%–90% local control rates [83]. 
 
With regard to chemotherapy, drugs active in sarcomas, doxorubicin, ifosfamide, may 
prove active in chondrosarcoma, especially in high-grade lesions (81, 87new). The 
activity of gemcitabine in combination with taxotere has been reported [84], and a 
potential role for mTOR inhibitors in combination with cyclophosphamide has been 
suggested [IVC]. 
 
giant cell tumour of bone 
Giant cell tumour (GCT) of bone is a relatively rare, locally aggressive progressive 
tumour of the skeleton. GCT is Although classified in the intermediate category as 
benign as, GCT can be aggressive and recurs locally in up to 50% of cases. Soft tissue 
extension is significantly associated with the risk of local recurrence. Up to 5% of GCTs 
metastasise to the lungs and spontaneous transformation to a high-grade malignancy 
occurs in 1%–3% of patients. Giant cell tumorss of bone contain mutations in the 
H3F3A gene (predominantly at the G34 position) which can be detected using 
mutation analysis or immunohistochemistry using mutation specific antibodies.  The 
molecular driver of GCT are mutations in histone H3. 
 
Treatment options include intralesional curettage with or without adjuvant or en bloc 
excision. Radiotherapy can provide a satisfactory local control in GCT (5-yr control 
rate 80%)[85]. However, the use of radiotherapy can be associated with a risk of GCT 
transformation into a high-grade sarcoma and can make surgical resection challenging 
if required. Therefore, the use of radiation therapy in GCTs should always be 
discussed in a multidisciplinary setting and limited to cases in which surgery leads to 
unacceptable morbidity and denosumab is ineffective or contra-indicated (LOE IV, 
GOR D). Denosumab, a human monoclonal antibody to RANKL, known to be 
overexpressed in GCT, is standard treatment in large or unresectable or metastatic 
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GCT (LOE III, GOR A). There is increasing evidence that, if being used preoperatively[p83], 
prior to curettage, surgery is best carried out after a few months treatment, as 
otherwise extensive ossification may take place, making it difficult to define the extent 
of the lesion. It can also be used in unresectable disease and rare metastatic disease. 
In this setting treatment interruption is usually followed by progression, so that 
treatment needs to be maintained [86]. Potential dental[Hans84][p85] and skeletal side effects need 
to be monitored (osteonecrosis of the jaw, atypical fractures) [IIA]. [AF86]There are currently 
no ongoing trials to define the optimum use of DenosumabThe optimal schedule and 
duration of treatment with denosumab in surgically unsalvageable GCTs is still to be 
settled, and the possible long-term side effects are still largely unknown.  
Radiation in selected cases (risk of high-grade sarcoma to be 
mentioned)Radiotherapy can provide a satisfactory local control in GCT (5-yr control 
rate 80%)[85]. However, the use of radiotherapy can be associated with a risk of GCT 
transformation into a high-grade sarcoma and can make surgical resection challenging 
if required. Therefore, the use of radiation therapy in GCTs should always be 
discussed in a multidisciplinary setting and limited to cases in which surgery leads to 





Chordomas are very rare tumours, arising from the remnants of the notochord into the 
sacrum (50%), skull base (30%) and mobile spine (20%). Extraskeletal cases have 
also been reported, but are extremely rare. 
 
Median age is 60 years, but skull base presentations can also affect a younger 
population, including children and adolescents.   Chordoma is a low-grade but locally-
invasive malignancy. Dedifferentiated cases are observed in 5% of patients. The 
metastatic potential of chordoma is ∼30%. Metastases usually appear late in the 
natural history of disease, mostly after local recurrence. 
 
Chordoma prognosis is more related to local aggressiveness than to metastases. 
Chordoma is a tumour showing notochordal differentiation. Brachyury is a transcription 
factor involved in notochord differentiation and isit is expression is the diagnostic 
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hallmark for conventional chordoma [87]. Immunohistochemistry positivity for 
brachyury is strongly recommended to confirm diagnosis. Dedifferentiated chordomas 
may lose brachyury expression. Genomic alterations of brachyrury genes 
(duplications) are also frequent in familial and sporadic forms along with activating  
mutations of the PI3K gene activated mutations (92new).  
 
Due to the rarity and long natural history of the disease, the quality of evidence 
available for more common tumour types is currently beyond reach for chordoma. In 
fact, only a few phase II trials are available and most published data are from case 
series and/or retrospective.  Chordoma management needs to be carried out at 
referral centres and/or referral networks, with a multidisciplinary team including expert 
pathologists and radiologists, surgeons familiar with musculoskeletal tumours and site 
of surgery, expert radiation oncologists with access to hadron facilities, dedicated 
medical oncologists and a palliative care team. All diagnostic and therapeutic 
procedures should be discussed in a multidisciplinary expert team. 
 
MRI is the best modality for local staging. CT scan should be used in the case of 
diagnostic doubt. Chordoma should be differentiated from benign notochordal lesions 
and, if radiological appearance is typical for these, biopsy is not recommended unless 
the lesion changes over time [88]. Preoperative core-needle biopsy is recommended. 
The biopsy track needs to be included in the surgical resection. In the case of skull 
base chordoma, preoperative biopsy can be avoided in selected cases[p89]. 
 
Tumour location is the most relevant variable to define the primary tumour treatment. 
The quality of surgical margins is the most important prognostic factor. En bloc R0 
resection is standard treatment, when it is feasible and sequelae are accept- 
able/accepted by the patient, with an expected 5-year recurrence-free survival of 50%. 
If en bloc R0 resection is not feasible, definitive radiation therapy alone should always 
be considered as a valid alternative. Local relapse has extremely poor survival rates 
and local control is rarely achievable. Supportive care should be incorporated into the 
treatment from the beginning. 
 
For skull base and upper cervical tract chordoma, R1–R2 surgery plus high-dose 
radiation therapy is the treatment of choice [89-91]. 
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For sacral chordoma, surgery should definitely be offered as the first choice in case 
chordoma arises from S4 and below. Surgery should always be discussed in the 
context of other alternatives for tumours originating above S3, since surgery is always 
followed by important neurological sequelae. Surgery is the primary standard choice 
for tumours originating from S3, especially if the preservation of S2 roots is possible, 
as it may result in some neurological recovery (40% of cases) [92-94]. 
 
Hadrons, i.e. high-dose protons or carbon ions, are superior to photons physically and 
in terms of irradiation of non-target lesions, although no randomised trials are available 
to assess the benefit of hadrons compared with photons in chordoma. Since hadrons 
allow lower doses to be given to normal tissues, they should be considered the 
treatment of choice. Advanced technology photons could be used in the case of 
unavailability or non-accessibility of protons and ions, and every time they show similar 
dose distribution to the target and critical structures. Due to the relative radiation 
resistance of chordomas, a high-dose up to at least 74 GyE in conventional 
fractionation (1.8–2 GyE) for photon and proton therapy is required [83, 95, 96]. 
 
Indications for definitive radiation therapy are: unresectable disease; inoperable 
patients; neurological impairment not accepted by the patient. Radiation therapy 
should be considered in the case of R2 or R1 resections. The use of 
adjuvant/neoadjuvant radiation therapy needs to be discussed with the single patient 
and prospective studies encouraged.   
 
Patients who have local recurrences are unlikely to be cured by any local salvage 
treatment[p90]. In the case of local relapse, the choice of treatment can include surgery 
and/or radiation therapy and/or systemic treatment, balancing morbidity and quality of 
life. 
 
For oligometastatic disease, surgery/radiofrequency ablations/stereotactic radiation of 
metastases can be considered in selected cases. Chemotherapy is inactive. An 
exception can be high-grade dedifferentiated chordoma (anecdotal responses to 
chemotherapy have been reported).  There is uncontrolled phase II evidence that 
imatinib can be beneficial in advanced chordoma in terms of progression-free survival 
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and mainly non-dimensional tumour responses [97]. Its role within the treatment 
strategy deserves further evaluation. However when other treatments are no longer 
possible it could certainly be considered if available.. There are data on the activity of 
epidermal growth factor receptor and vascular endothelial growth factor receptor 
inhibitors. Prospective studies are ongoing.  
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Small round cell sarcoma III 
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Follow-up, long term implications and survivorship 
Follow-up is designed to detect either local recurrence or metastatic disease at a time 
when early treatment is still possible and might be effective. Follow-up of high-grade 
tumours should include both a physical examination of the tumour site and 
assessment of the function and possible complications of any reconstruction. Local 
imaging and chest X-ray/CT should be the norm. Though strict rules cannot be 
provided in the absence of any formal validation, a recommended follow-up policy may 
foresee intervals between checks after the completion of chemotherapy approximately 
every 3–6 months for the first 2 years; every 6 months for years 3–5; every 6-12 
months for years 5–10, and thereafter every 0,5-1-2 years according to local practice 
and other factors[p92]. Chest-CT, if used instead of chest X-rays, should be performed 
with low-dose, radiation sparing techniques, particularly in younger patients who will 




In the case of low-grade bone sarcoma, the frequency of follow-up visits may be lower 
(e.g. 6 months for 2 years and then annually[p94]). Late metastases as well as local 
recurrences and functional deficits may occur >10 years after diagnosis and there is 
no universally accepted stopping point for tumour surveillance[p95]. 
 
In ES, where osseous metastases are likely, isotope bone scanning can be used in 
addition, but its use needs to be weighed against the additional radiation exposure, 
particularly in younger patients. More modern techniques (e.g. PET or whole-body 
MRI) are increasingly being adopted into routine practice, but are likely to require 
further evaluation in clinical trials[p96].  
 
It is important to evaluate the long-term toxic effects of chemotherapy and 
radiotherapy[p97], if appropriate. Monitoring for late effects should be continued for >10 
years after treatment, depending on the chemotherapy protocol and radiation used 
and in conjunction with late effects services when available. Long term cardiac 
evaluation is of major importance since it has been shown that deterioration of 
cardiac function can still occur decades after anthracycline treatment (ref).[p98] 
 
Secondary cancers may arise in survivors of bone sarcomas, either related to, or 
independent of, irradiation. Secondary leukaemia, particularly acute myeloid 
leukaemia, may rarely be observed following chemotherapy, as early as 2–5 years 
after treatment.  Developments in genetic understanding of bone sarcoma point to the 
importance of may require obtaining a detailed family history and of genetic evaluation 
in high-risk families[p99]. Patients with cancer predisposition syndromes (e.g., Li-Fraumeni 
or Rothmund-Thomson syndromes) require special care and follow-up.       
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Table 1. Levels of evidence and grades of recommendation (adapted from the 
Infectious Diseases Society of America-United States Public Health Service 
Grading Systema) 
 
Levels of evidence 
I Evidence from at least one large randomised, controlled trial of good 
methodological quality (low potential for bias) or meta-analyses of 
well-conducted randomised trials without heterogeneity 
II Small randomised trials or large randomised trials with a suspicion of 
bias (lower methodological quality) or meta-analyses of such trials or 
of trials with demonstrated heterogeneity 
III Prospective cohort studies 
IV 
 
Retrospective cohort studies or case–control studies  
 
V Studies without control group, case reports, experts opinions 
 
Grades of recommendation 
A Strong evidence for efficacy with a substantial clinical benefit, 
strongly recommended 
B Strong or moderate evidence for efficacy but with a limited clinical benefit, 
generally recommended 
C Insufficient evidence for efficacy or benefit does not outweigh the risk or 
the disadvantages (adverse events, costs, ...), optional  
D              Moderate evidence against efficacy or for adverse outcome, generally not 
recommended 
E              Strong evidence against efficacy or for adverse outcome, never 
recommended 
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